albumin binding raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-02-08. Anything still debated is marked as such rather than presented as settled.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
| Property | Value | Notes |
|---|---|---|
| Compound class | Synthetic triple-agonist peptide | Single linear chain carrying three receptor activities |
| Reported molecular weight | Approximately 4731 Da | Calculated from the published sequence; sources vary slightly |
| Appearance | White to off-white lyophilized powder | Typical of purified research-grade peptides |
| Solubility | Freely soluble in water; poorly soluble in nonpolar solvents | Dissolves in aqueous buffer near neutral pH |
| Storage of dry powder | -20 °C or below, desiccated, protected from light | Avoid repeated temperature cycling |
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Although sublingual administration of estradiol has a relatively short duration, the medication can be administered multiple times per day in divided doses to compensate for this. Studies that used high doses of sublingual estradiol in the treatment of severe postpartum depression have administered a dose of 1 mg 3 to 8 times per day. In one study, which administered a mean total dosage of sublingual estradiol of 4.8 mg/day, estradiol levels remained elevated at about 130 pg/mL on average in the morning before the first dose of the day. Oral micronized estradiol valerate tablets can be taken sublingually as well. The administration of 2 mg oral micronized estradiol valerate tablets (Progynova, Schering) sublingually 3 or 4 times per day resulted in circulating estradiol levels of about 290 pg/mL to 460 pg/mL in premenopausal women (time of measurements not given). Steady-state levels of estradiol were achieved within about 5 or 6 days. Levels of progesterone, luteinizing hormone, and follicle-stimulating hormone were all considerably suppressed, and ovulation, as well as the associated mid-cycle hormonal surges, were prevented. Sublingual estradiol valerate is used for cycle control in egg donation and surrogacy in cisgender women and is used in hormone therapy for transgender women. Cyclodextrin-containing formulations of sublingual estradiol with improved water solubility and absorption have been developed and studied.
The St. Augustine Monster is the name given to a large carcass, originally postulated to be the remains of a gigantic octopus, that washed ashore on the United States coast near St. Augustine, Florida in 1896. It is sometimes referred to as the Florida Monster or the St. Augustine Giant Octopus and is one of the earliest recorded examples of a globster. The species that the carcass supposedly represented has been assigned the binomial names Octopus giganteus (Latin for "giant octopus") and Otoctopus giganteus (Greek prefix: oton = "ear"; "giant-eared octopus"), although these are not valid under the rules of the ICZN. A 1995 analysis concluded that the St. Augustine Monster was a large mass of the collagenous matrix of whale blubber, likely from a sperm whale.
== Services == The Instituto Universitario de Restauración del Patrimonio is divided into two areas: the area of intervention in the Pictorial and Sculptural Heritage and the area of intervention in the Architectural Heritage, and a Training and Dissemination area. The area of intervention in the pictorial and sculptural heritage operates in both basic research and applied research in seeking to acquire new knowledge to develop new products, techniques, processes, methods and systems that improve existing ones. The area of intervention in the Pictorial and Sculptural Heritage consist in restoration workshops:
Bird collections are used for a wide variety of purposes. All biological species including those of birds are represented by a holotype, the vast majority of which are full specimens (mostly skins) and in modern times explicitly designated in the original description of the taxon. All other putative members of the species may be compared to the holotype to confirm their identification. Rigorous studies of avian taxonomy are based on specimens from bird collections. Taxonomic studies rely on morphological and genetic characters to determine species limits and evolutionary relationships. Museum specimens have been the preferred source for scoring these characteristics, as they allow studies to be replicated – anyone may go back and repeat the study using the same specimens to verify the conclusions. However, it has alternatively been argued that such re-examination can be undertaken from archived photographs without killing the study piece.
Sources: en.wikipedia.org
==== Soil preparation ==== In tropical cultivation, soil erosion is a major problem, requiring soil treatment to be as shallow as possible. Plowing is required only for high planting densities. In low planting densities, digging pits and refilling them with soil is preferable to ensure good root system penetration without causing too much land erosion. Optimal pits are 30–50 cm (12–20 in) deep and 20–40 cm (8–15+1⁄2 in) wide.
== Biological applications == Chemiluminescence has been applied by forensic scientists to solve crimes. In this case, they use luminol and hydrogen peroxide. The iron from the blood acts as a catalyst and reacts with the luminol and hydrogen peroxide to produce blue light for about 30 seconds. Because only a small amount of iron is required for chemiluminescence, trace amounts of blood are sufficient. In biomedical research, the protein that gives fireflies their glow and its co-factor, luciferin, are used to produce red light through the consumption of adenosine triphosphate (ATP). This reaction is used in many applications, including the effectiveness of cancer drugs that choke off a tumor's blood supply. This form of bioluminescence imaging allows scientists to test drugs in the pre-clinical stages cheaply. Another protein, aequorin, found in certain jellyfish, produces blue light in the presence of calcium. It can be used in molecular biology to assess calcium levels in cells. What these biological reactions have in common is their use of ATP as an energy source. Though the structure of the molecules that produce luminescence is different for each species, they are given the generic name of luciferin. Firefly luciferin can be oxidized to produce an excited complex. Once it falls back down to a ground state a photon is released. It is very similar to the reaction with luminol.
Roseanne Park. Musician/Performer. For services to the United Kingdom COP 26 Presidency and advocacy for the 2021 United Nations Climate Change Conference of the Parties. Gina Cecile Petrie. Director, Department of Environment, Cayman Islands. For services to the Environment and to the community in the Cayman Islands. Richard Anthony Power. Orthopaedic Surgeon, University Hospitals of Leicester NHS Trust; Chair, Health Action Leicester in Ethiopia. For services to Health in Gondar, Northern Ethiopia. Natalie Ray Pray. Former President, the St George's Society, New York, United States of America. For services to UK/US Cultural Relations and to Philanthropy. Phillip Christopher Robinson. Team Leader, Foreign, Commonwealth and Development Office. For services to National Security. James Andrew Rogers. Head of Coordination, Windsor Framework Taskforce, Foreign, Commonwealth and Development Office. For services to British Foreign Policy. Lynette Silver. Historian and Author. For services to British Families of World War II personnel. Claire Sonia van Straubenzee. Founder and Trustee, The Henry van Straubenzee Memorial Fund. For services to Children's Education in Uganda. Edward Robert Syfret. Angola Programme Manager, the HALO Trust. For services to Humanitarian Demining in Angola. Margery Anne Taylor. District Treasurer and District Training Officer, Royal British Legion, Spain South. For services to Veterans in Spain. Jacqueline Barbara Teasdale (Tig James). Co-President, British in Portugal. For services to the British Community in Portugal. John Robert Thurlow.
== International Organization for Standardization (ISO) == CLSI participates in the development of international standards as the Secretariat of ISO Technical Committee (TC) 212, clinical laboratory testing and in vitro diagnostic test systems. This responsibility was delegated to CLSI by the American National Standards Institute (ANSI), an ISO member body. CLSI also serves as the administrator for the US Technical Advisory Committee (TAG) for ISO/TC 212.
== Safety == Due to reclassification as UN0508, a class 1.3C explosive, hydroxybenzotriazole and its monohydrate crystal are no longer allowed to be transported by sea or air as per 49CFR (USDOT hazardous materials regulations). However, UNECE draft proposal ECE/TRANS/WP.15/AC.1/HAR/2009/1 has been circulated to UN delegates and, if implemented, would amend current regulations thus allowing for the monohydrate crystal to be shipped under the less-stringent code of UN3474 as a class 4.1 desensitized explosive. HOBt was demonstrated to not exhibit dermal corrosion or irritation but did exhibit eye irritation. The sensitization potential of HOBt was shown to be low (non-sensitizing at 1% in LLNA testing according to OECD 429).
Sources: en.wikipedia.org
In their 2024 description of Tyrannosaurus mcraeensis, Dalman et al. recovered similar results to previous analyses, with Tyrannosaurus as the sister taxon to the clade formed by Tarbosaurus and Zhuchengtyrannus, called the Tyrannosaurini. They also found support for a monophyletic clade containing Daspletosaurus and Thanatotheristes, typically referred to as the Daspletosaurini.
== Function == Cystinosin functions as a symporter which actively transports protons and cystine, the oxidized cysteine dimer, out of the lysosome. Cystinosin only transports L-CySS while other cystine transporters will work on various amino acids. If cystine builds up in the lysosome it will inhibit the normal functioning of the organelle making the transport function important in the regular functioning of cells. Cystinosin has also been discovered in melanosomes and has been linked to the control and regulation of melanin.
Nearly a decade after the war, the Romans set up colonies at Tempsa and Kroton (Croto in Latin) in 194 BCE, Copiae in the territory of Thurii (Thurium in Latin) in 193 BCE, and Vibo Valentia in the territory of Hipponion in 192 BCE. Starting in the third century BCE, the name Calabria was given to the Adriatic coast of the Salento peninsula in modern Apulia. In the first century BCE this name extended to the entirety of the Salento, when the Roman emperor Augustus divided Italy into regions and modern Calabria was known as Regio III Lucania et Bruttii. From 186 BCE, repression of the Bacchanalia, and of the Greek cult of Bacchus, is triggered throughout Magna Graecia as part of a plan to Romanize southern Italy. Between 136 and 132 BCE, the First Servile War was fought in Sicily. The Syrian slave Eunus gathered some 200,000 serfs, proclaiming himself king, and for four years held out against the Roman legions from Enna and Taormina. Eventually Rome crushed the repression and crucified 20,000 slaves throughout the island. The Servile war was an expression of the slave class' discontent, on whom the entire Roman economy rested. In 132 BCE the consul Popilius Lenate ordered the construction of the Via Capua-Rhegium, also known as Via Popilia, which, tracing the route now occupied by A2 Highway and State Road 18 Tirrena, reached Reggio. In this period the main towns were Cosenza, Crotone, Temesa, Turi, Vibo Valentia Taurianum, and Reggio. Between 91 and 89 BCE the Social War was fought, at the end of which the Roman Senate granted the Italics Roman citizenship.
== Key people == The Santa Monica-based startup was founded in September 2011 by Trevor Bezdek and former Facebook executives Doug Hirsch and Scott Marlette. Marlette was one of the first 20 employees at Facebook and built Facebook's photo application. In 2005, Hirsch was the Vice President of Product at Facebook, working closely with Mark Zuckerberg. Bezdek and Hirsch served as co-chief executive officers until April 2023, when they stepped down from those roles and technology executive Scott Wagner was appointed interim chief executive officer. Bezdek became chair of the board, while Hirsch took on the role of chief mission officer. In December 2024, GoodRx announced that healthcare executive Wendy Barnes would become president and chief executive officer effective January 1, 2025. As of 2025, Barnes serves as the company's CEO, while Trevor Bezdek and Scott Wagner serve as co-chairs of the board, and Doug Hirsch remains involved as a co-founder and senior executive.
Sources: en.wikipedia.org
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.
No. As of the most recent public information it remains investigational in every jurisdiction. Material sold under this name outside trials is a research chemical, not an approved medicine. Current status should always be checked against regulator notices.
Dual agonists act on two receptors, usually GIP and GLP-1. Retatrutide adds glucagon receptor activity, which is associated with increased energy expenditure. Whether that third component adds clinically meaningful benefit over dual agonism remains an open question.
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.